Dianthus Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Dianthus Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 56% to $2,826,000. Profit margin reached -1541%. Total operating expenses were $51,000,000.
Profit Margin
| 2016 | 0 | -9.43M | |
|---|---|---|---|
| 2017 | 0 | -35.49M | |
| 2018 | 0 | -57.51M | |
| 2019 | 0 | -76.76M | |
| 2020 | 0 | -74.93M | |
| 2021 | 1.47M | -13.10M | -888.14% |
| 2022 | 6.41M | -28.47M | -443.76% |
| 2023 | 2.82M | -43.55M | -1541.22% |
DNTH Income Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue | 2.82M | 6.41M | 1.47M | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 355K | 147K | 2.02M | 1.97M | 1.84M | 0 | 376K | 0 |
Gross profit | 2.47M | 6.27M | -544K | -1.97M | -1.84M | 0 | -376K | 0 |
Operating exp. | ||||||||
Research and development | 32.84M | 29.37M | 12.60M | 48.63M | 57.36M | 41.34M | 27.89M | 5.78M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | -376K | 0 |
Total operating expenses | 51M | 36.12M | 14.56M | 76.72M | 81.12M | 59.96M | 35.35M | 9.26M |
Operating income | -48.17M | -29.70M | -13.08M | -78.70M | -82.96M | -59.96M | -35.72M | -9.26M |
Other income (expenses), net | 4.61M | 84K | -26K | 3.76M | 6.2M | 2.44M | 236K | -163K |
Income before tax | -43.55M | -28.47M | -13.10M | -74.93M | -76.76M | -57.51M | -35.49M | -9.43M |
Income tax expense | 0 | -1.28M | -1.99M | 7.53M | 6.2M | 2.44M | 236K | 0 |
Net income | -43.55M | -28.47M | -13.10M | -74.93M | -76.76M | -57.51M | -35.49M | -9.43M |
Earnings per share | ||||||||
Basic EPS | -8.45 | -32.57 | -3.82 | -27.3 | -33.18 | -3.13 | -16.05 | -0.44 |
Diluted EPS | -8.45 | -32.57 | -3.82 | -27.3 | -33.18 | -3.13 | -16.05 | -0.44 |
| Data source | Data source | Data source | Data source |